Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor

Molecular Cancer Therapeutics

Volumn 2, Issue 4, 2003, Pages 371-382

  Miknyoczki, Sheila J ^a   Jones Bolin, Susan ^a   Pritchard, Sonya ^a   Hunter, Kathryn ^a   Zhao, Hugh ^a   Wan, Weihua ^a   Ator, Mark ^a   Bihovsky, Ronald ^a   Hudkins, Robert ^a   Chatterjee, Sankar ^a   Klein Szanto, Andres ^a,b   Dionne, Craig ^a   Ruggeri, Bruce ^a  

^a CEPHALON INC   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CEP 6800; CEP-6800; CISPLATIN; DACARBAZINE; DRUG DERIVATIVE; ENZYME INHIBITOR; FUSED HETEROCYCLIC RINGS; IRINOTECAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TEMOZOLOMIDE;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL CYCLE; CELL DIVISION; CELL LINE; CHEMICAL MODEL; DNA DAMAGE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; KINETICS; LUNG TUMOR; MOUSE; NUDE MOUSE; TIME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL CYCLE; CELL DIVISION; CELL LINE; CELL LINE, TUMOR; CISPLATIN; DACARBAZINE; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; KINETICS; LUNG NEOPLASMS; MICE; MICE, NUDE; MODELS, CHEMICAL; NEOPLASM TRANSPLANTATION; POLY(ADP-RIBOSE) POLYMERASES; TIME FACTORS;

EID: 0242588748     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. D'Amours, D., Desnoyers, S., D'Silva, I., and Poirier, G. G. Poly(ADP-ribosyl) ation reactions in the regulation of nuclear functions. Biochem. J., 342: 249-268, 1999. (Pubitemid 29425344)
2. Griffin, R. J., Curtin, N. J., Newell, D. R., Golding, B. T., Durkacz, B. W., and Calvert, A. H. The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy. Biochimie, 77: 408-422, 1995.
3. Tentori, L., Portarena, I., and Graziani, G. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol. Res., 45:73-85, 2002. (Pubitemid 35425647)
4. Smith, S. The world according to PARP. Trends Biochem. Sci., 26:174-179, 2001. (Pubitemid 32197577)
5. Bürkle, A., Chen, G., Küpper, J-H., Grube, K., and Zeller, W. J. Increased poly(ADP-ribosyl)ation in intact cells by cisplatin treatment. Carcinogenesis (Lond.), 14: 559-561, 1993. (Pubitemid 23149982)
6. Delaney, C. A., Wang, L-Z., Kyle, S., White, A. W., Calvert, A. H., Curtin, N. J., Durkacz, B. W., Hostomsky, Z., and Newell, D. R. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose)polymerase inhibitors in a panel of human tumor lines. Clin. Cancer Res., 6: 2860-2867, 2000. (Pubitemid 30482128)
7. Canan-Koch, S., Thoresen, L., Tikhe, J., Maegley, K., Li, J., Yu, X-H., Almassy, R., Zhang, K., Zook, S., Kumpf, R., Zhang, R., Curtin, N. J., Delaney, C. A., Kyle, S., Thomas, H., Wang, L-Z., Newell, D. R., Hostomsky, Z., and Webber, S. Structure activity relationship, crystal structure, and biological evaluation of potent poly(ADP-ribose) polymerase-1 inhibitors. Am. Chem. Soc. 220th National Meeting, MEDI-007: 2000.
8. Masutani, M., Nozaki, T., Nakamoto, K., Nakagama, H., Suzuki, H., Kusuoka, O., Tsutsumi, M., and Sugimura, T. The response of Parp knockout mice against DNA damaging agents. Mutat. Res., 462: 159-166, 2000. (Pubitemid 30190223)
9. Kato, T., Suzumura, Y., and Fukushima, M. Enhancement of bleomycin activity by 3-aminobenzamide, a poly(ADP-ribose) synthesis inhibitor, invitro and in vivo. Anticancer Res., 8: 239-244, 1988.
10. Griffin, R. J., Srinivasan, S., Bowman, K. J., Calvert, A. H., Curtin, N. J., Newell, D. R., Pemberton, L. C., and Golding, B. T. Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP). J. Med. Chem., 5247-5256, 1998. (Pubitemid 29016316)
11. Mattern, M. R., Mong, S-M., Bartus, H. F., Mirabelli, C. K., Crooke, S. T., and Johnson, R. K. Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. Cancer Res., 47: 1793-1798, 1987. (Pubitemid 17056678)
12. Bowman, K. J., White, A., Golding, B. T., Griffin, R. J., and Curtin, N. J. Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU 1025 and NU 1064. Br. J. Cancer, 78:1269-1277, 1998. (Pubitemid 28495236)
13. Bowman, K. J., Newell, D. R., and Curtin, N. J. Differential effects of the poly(ADP-ribose) polymerase (PARP) inhibitor NU 1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br. J. Cancer, 84: 106-112, 2001. (Pubitemid 32102513)
14. Liu, L., Taverna, P., Whitacre, C. M., Chatterjee, S., and Gerson, S. L. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clin. Cancer Res., 5: 2908-2917, 1999. (Pubitemid 29493970)
15. Tentori, L., Leonetti, C., Scarsella, M., d'Amati, G., Portarena, I., Zupi, G., Bonmassar, E., and Graziani, G. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood, 15: 2241-2244, 2002. (Pubitemid 34525513)
16. Ator, M., Bihovsky, R., Chatterjee, S., Dunn, D., and Hudkins, R. Novel multicyclic compounds and their use thereof. Patent WO 01/85686 A2, 2001.
17. Jansen, J. M., Zwart, B., Hulscher, S. T. M., Giaccone, G., Pinedo, H. M., and Boven, E. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Int. J. Cancer, 70: 335-340, 1997. (Pubitemid 27099604)
18. Boulton, S., Pemberton, L. C., Curtin, N. J., Griffin, R. J., Golding, B. T., and Durkacz, B. W. Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP) polymerase inhibitors. Br. J. Cancer, 72: 849-856, 1995.
19. 2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res., 61: 1975-1963, 2001.
20. Links, M., Ribeiro, J., Friedlander, M., and Russell, P. J. Regulation and deregulation of G2 checkpoint proteins with cisplatin. Anticancer Res., 18: 4057-4066, 1998. (Pubitemid 29043612)
21. te Poele, R. H., and Joel, S. P. Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines. Br. J. Cancer, 81: 1285-1293, 1999.
22. Birchler, M., Fiocchi, E. M., and Jones, B. E. A quantitative method for determining in vivo activation of PARP and biological activity of inhibitors of the enzyme. Society of Neurosci. Abs., 26: 17, 2000.
23. Schiller, J. H., and Bittner, G. Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: Effects on tumor neovascularization. Clin. Cancer Res., 5:4287-4294, 1999. (Pubitemid 30013817)
24. 6-Methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin. Cancer Res., 6: 4110-4118, 2000.
25. Dionne, C. A., Camoratto, A. M., Emerson, E., Neff, N., Vaught, J., Murakata, C., Djakiew, D., Lamb, J., George, D., and Isaacs, J. T. Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin. Cancer Res., 4:1887-1898, 1998. (Pubitemid 28369172)
26. Thompson, J., Zamboni, W. C., Cheshire, P. J., Lutz, L., Luo, X., Li, Y., Houghton, J., Stewart, C. F., and Houghton, P. J. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin. Cancer Res., 3: 423-431, 1997. (Pubitemid 27158067)
27. Gradzka, I., Skierski, J., and Szumiel, I. DNA repair, cell cycle progression and cell death following camptothecin treatment in two murine lymphoma L5178Y sublines. Cell Biochem. Func., 16: 239-252, 1998. (Pubitemid 28523758)
28. Menissier-de Murcia, J., Niedergang, C., Trucco, C., Ricoul, M., Dutrillaux, B., Marks, M., Oliver, J., Masson, M., Dierich, A., LeMeur, M., Walztinger, C., Chambon, P., and de Mercia, G. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and cells. Proc. Natl. Acad. Sci. USA, 94: 7303-7307, 1997. (Pubitemid 27345310)
29. Trucco, C., Oliver, J., de Mercia, G., and Menissier-de Murcia, J. DNA repair defect in poly(ADP-ribose) polymerase-deficient cell lines. Nucleic Acid Res., 26: 2644-2649, 1998. (Pubitemid 28297377)
30. Goldwasser, F., Bae, I., Valenti, M., Torres, K., and Pommier, Y. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res., 55: 2116-2121, 1995.
31. Brada, M., Judson, I., Beale, P., Reidenberg, P., Statkevich, P., Dugan, M., Batra, V., and Cutler, D. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br. J. Cancer, 81: 1022-1030, 1999. (Pubitemid 29516147)
32. Chen, G., and Pan, Q. Potentiation of the antitumor activity of cisplatin in mice by 3-aminobenzamide and nicotinamide. Cancer Chemother. Pharmacol., 22: 303-307, 1988.
33. Schreiber, V., Ame, J-C., Dolle, P., Schultz, I., Rinaldi, B., Fraulob, V., Menissier-de Murcia, J., and de Mercia, G. Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC. J. Biol. Chem, 277: 23028-23036, 2002. (Pubitemid 34967289)
34. Plowman, J., Waud, W. R., Koutsoukos, A. D., Rubinstein, L. V., Moore, T. D., and Grever, M. R. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts in synergism with 1, 3-Bis(2-chloroehtyl)-1-nitrosurea. Cancer Res., 54: 3793-3799, 1994.
35. 2/M cell accumulation induced by Temozolomide in malignant glioma cells. Glia, 40: 44-54, 2002.
36. Furman, W. L., Stewart, C. F., Poquette, C. A., Pratt, C. B., Santana, V. M., Zamboni, W. C., Bowman, L. C., Ma, M. K., Hoffer, F. A., Meyer, W. H., Pappo, A. S., Walter, A. W., and Houghton, P. J. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J. Clin. Oncol., 17: 1815-1824, 1999. (Pubitemid 29269252)
37. Racz, I., Tory, K., Gallyas F., Jr., Berente, Z., Osz, E., Laszlo, J., Bernath, S., Sumegi, B., Rabloczky, G., and Nagy-Literati, P. BGP-15- a novel poly(ADP-ribose) polymerase inhibitor-protects against nephrotoxicity of cisplatin without compromising its antitumor activity. Biochem. Pharmacol., 63: 1099-1111, 2002. (Pubitemid 34267025)